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Introduction
The overall outcome of treatment of patients of older age with acute myeloid leukemia (AML) has remained highly unsatisfactory. In patients > 60 years complete response (CR) rates are 45-60% only, while median disease-free survival (DFS) values have been estimated at less than 12 months and the 4-5 year overall survival (OS) rates are approximately 10% [1] [2] [3] [4] [5] .
A potentially important biologic factor that may account for chemotherapy resistance of AML in patients of higher age is the high incidence of the intrinsic multidrug resistance (MDR) phenotype of leukemic blast cells 6 . The MDR phenotype results from expression of the MDR1 gene 7, 8 and its 170-kd protein product, Pglycoprotein (P-gp) 9 , also designated as ABCB1 10 . P-gp is a transmembrane protein that acts as an energy-dependent drug efflux pump for chemotherapeutic drugs such as the anthracyclines and epipodophyllotoxins, commonly used in AML therapy.
Increased P-gp expression and enhanced drug efflux have been reported with increasing age, i.e. from 17%
in patients under the age of 35, 27% in 35-50 years and 39% in patients over 50 years 11 to 71% in a group with median age 68 years (range 56-88) 6 . In retrospective studies MDR1/P-gp expression was associated with lower CR rates and decreased OS and DFS in AML [12] [13] [14] [15] [16] . Also P-gp positivity of AML is associated with other adverse prognostic factors such as CD34 expression, secondary leukemia and unfavorable cytogenetics 6, 13, 14, 17 .
Based on these studies a rationale was developed for MDR1 modulation as a therapeutic approach 18 . A variety of non-cytotoxic agents, such as verapamil, quinine and cyclosporin A (CsA), inhibit the P-gp transporter through competition with other substrates for the binding sites of P-gp. These agents block P-gpmediated efflux of drugs from the intracellular compartment and increase the intracellular accumulation of MDR related drugs in MDR-positive cells 19, 20 . In addition, many of these P-gp reversal agents also block the elimination of cytostatic drugs from the molecular pores in the hepatobiliary canaliculi. By doing so they reduce hepatic elimination of antileukemic drugs like anthracyclines, which results in a prolonged half-life, an increase of the plasma area under the curve (AUC) and potentially increased toxicity from these agents 21 .
Randomized phase 2 and phase 3 studies with first-generation P-gp inhibitors in AML were mostly nonconclusive because of poor therapeutic benefit or unexpected interactions with the pharmacokinetics of the cytostatic agent 22, 23 . Quinine and verapamil 24 have a cardiotoxic risk profile which prohibits adequate dosing.
The second-generation P-gp inhibitor PSC-833 (Valspodar®) is a cyclosporin analogue which is 7-20 fold more potent than CsA in increasing DNR retention in MDR cells, while lacking the immunosuppression and nephrotoxicity. The dose-limiting toxicity is cerebellar ataxia, which is however transient and fully reversible [25] [26] [27] . Phase 1 and phase 2 studies suggest that substantial inhibition of P-gp can be achieved in vivo at clinically tolerable doses of both PSC-833 and DNR 28, 29 .
Here we report the results of an international, multicenter, open-label, randomized phase 3 trial of PSC-833 plus standard chemotherapy in 419 previously untreated elderly AML patients, performed under the auspices of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and the United Kingdom Medical Research Council (MRC). Two remission induction regimens of DNR/Ara-C and DNR/Ara-C/PSC-833 were compared for their effect on CR rate, event-free survival (EFS), DFS and OS. The effect of PSCFor personal use only. on July 15, 2017. by guest www.bloodjournal.org From 833 plus chemotherapy on these outcome parameters in relation to the P-gp status at diagnosis was also investigated.
Patients, materials and methods

Patients
Patients 60 years with previously untreated primary or secondary AML (M0-M2 and M4-M7, FAB classification adapted from Cheson et al 30 ) and WHO performance status 2 were eligible for this study.
Patients with secondary AML progressing from antecedent MDS were eligible if they had not been given chemotherapy previously. Antecedent MDS was defined by a duration of at least 4 months. Patients with promyelocytic leukemia (M3), blast crisis of chronic myeloid leukemia, previous Polycythemia Rubra Vera or primary myelofibrosis were not eligible. Other exclusion criteria were cytopathologically confirmed central nervous system (CNS) infiltration, neurosensory toxicity grade 2 or neurocerebellar toxicity grade 1 (NCIC Expanded Common Toxicity Criteria (CTC)), known to be positive for HIV, impaired hepatic or renal function (alanine amino transferase (ALT) and/or aspartate amino transferase (AST) 2.5 × institutional Upper Limit of Normal (IULN), alkaline phosphatase (AP) 2.5 × IULN, serum total bilirubin 1.5 × IULN and serum creatinine 1.5 × IULN after adequate hydration), those receiving treatment interacting with CsA, previous surgery within 2 weeks or investigational therapy or radiotherapy within 4 weeks of study entry, other primary malignancy except basal cell carcinoma of the skin or stage 1 cervical carcinoma within the last 5 years, concurrent severe and/or uncontrolled medical condition, psychological, intellectual or sensory dysfunction which was likely to impede ability to understand and comply with study requirements, or severe cardiac or pulmonary disease.
The study was approved by the ethics committees of the participating institutions, and was conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent.
Registration and randomization procedures
Patients were randomly assigned to one of two induction chemotherapy regimens without or with PSC-833, using a validated, voice-activated telephone system, and stratified according to age (60-65, 66-70 and 71 or above) and secondary AML (no or yes). 
Treatment
Definition of endpoints
In this analysis, CR was defined as a normocellular bone marrow (BM) with < 5% blasts, no Auer rods and no evidence of extramedullary involvement. Data on PB recovery within 60 days after start of a cycle was not always available, and was not considered as a criterion for CR. When the BM blast cell count remained between 5 and 25% but was reduced by at least 50% in comparison to the initial value, a patient was Early death was defined as death during the first 7 days of the first induction cycle.
EFS was determined from the date of randomization until no CR on induction therapy, relapse after CR or death in CR, whichever came first. Patients who did not attain a CR were considered failure at 1 day after randomization. DFS was determined for all patients who achieved CR and was calculated from the date of CR until relapse or death, whichever came first. OS was measured from randomization until death from any cause. Patients still alive at the date of last contact were censored.
Analysis of P-gp expression and function in AML samples by flow cytometry
A BM aspirate of 3-10 ml was collected in a tube containing 0. Fluorescence was measured using a FACScalibur (Becton Dickinson).
Results are given as the ratio of the mean of cell-associated fluorescence of cells incubated with the anti-Pgp antibody divided by the mean of cell-associated fluorescence of cells incubated with the control mIgG2a
antibody.
Measurement of the function of P-gp. For measurement of the function of P-gp 34, 35 , the fluorescent compound rhodamine 123 (Rho123; Sigma) was used as a P-gp substrate. Cells were incubated for 1 hr at 37°C at 5% CO 2 in the absence and presence of 2 VM PSC-833. After this incubation, 200 ng/ml Rho123 was added to the cells. A sample was taken at t=0 min to correct for background fluorescence and at t=75 min to measure intracellular rhodamine accumulation.
To measure function of P-gp in CD34-positive cells, cells were labeled with PE-Cy5-labeled CD34 antibody or as a control PE-Cy5-labelled mIgG1 antibody (Immunotech).
Cells were incubated with 0.1 VM TO-PRO-3 to exclude non-viable cells. Fluorescence was measured using a FACScalibur.
Results are given as the ratio of the mean intracellular Rho123 fluorescence of cells exposed to PSC-833 divided by the mean intracellular Rho123 fluorescence of cells not exposed to PSC-833.
Interpretation.
As controls in each analysis, the drug-sensitive human myeloma cell line 8226 S and the drug-resistant variant 8226 D6 cells 36 were used. Taken all experiments together, the mean efflux ratio For personal use only. on July 15, 2017. by guest www.bloodjournal.org From CD34-positive cells, which could be the leukemic tumor cell population. Only patients with a subpopulation of more than 10% of positive cells are considered positive. Some patients had P-gp expression, but no function. These patients were considered negative, since it is possible that these patients express a nonfunctional P-gp. Some patients showed P-gp function, but no expression. These patients were considered positive, because of the possible clinical relevance of this phenomenon. P-gp assessment. For patients with P-gp data available, an integrated P-gp score (IPS) was based on the P-gp function, or if not available, on the expression ratios 
Cytogenetic analysis
Cytogenetic analysis of BM samples obtained at diagnosis was performed using standard cytogenetics techniques. All available cytogenetic reports were reviewed by two expert cytogeneticists. Chromosomal abnormalities were described according to the International System for Human Cytogenetics Nomenclature (ISCN 1995) 37 . Favorable risk was defined as the presence of t(8;21), inv(16) or t(16;16). Unfavorable risk was defined by the presence of monosomies or deletions of chromosomes 5 or 7, abnormalities of the long arm of chromosome 3(q21;q26), t(6;9), abnormalities involving the long arm of chromosome 11 (11q23) or complex cytogenetic abnormalities (defined as at least 3 unrelated cytogenetic clones). Patients who did not meet the criteria for favorable or unfavorable risk were classified as being intermediate risk.
Statistical considerations
The primary objective of the study was to compare EFS between the two treatment arms on an intention-totreat basis, i.e. patients were analyzed according assignment to treatment arm A (without PSC-833) or B (with PSC-833). To detect with a power of 80% an increase in 2-year EFS from 9.5% to 18% (two-sided significance level = 0.05), and assuming an accrual of 18 months and a follow up time of 12 months, 400 patients were required and 331 events had to be observed.
Secondary endpoints were CR rate, DFS and OS between the two treatment arms, safety and tolerability of the two treatment regimens, and the association between IPS and outcome and the interaction with additional PSC-833. The CR rate was compared between the two treatment arm using logistic regression 40 . The odds ratio (OR) was calculated with a 95% confidence interval (CI).
EFS, DFS and OS were estimated by the Kaplan-Meier method 41 , and 95% CIs were constructed. Survival analysis was performed using Cox regression 42 to see whether there was a difference in survival between the two treatment arms. The hazard ratios (HRs) and corresponding 95% CIs were determined for all three survival endpoints. Kaplan-Meier curves were generated to illustrate differences between the two treatment arms and compared using the log-rank test 43 . Competing risk analysis was used to calculate cumulative competing risks of treatment failure among patients with a CR (either relapse after CR or death in first CR).
Safety was analyzed using descriptive statistics to summarize the incidence of adverse events (AEs) and laboratory findings. Toxicity of the two regimens was assessed by laboratory evaluation, physical examination, vital signs and AE assessments. AEs were scored using the NCIC Expanded CTC.
All reported P-values are two-sided and a significance level = 0.05 was used.
Results
Patient characteristics
Between May 1997 and February 1999, 428 patients from 99 centers in 15 countries were randomized for study treatment. Eight patients were not eligible because of previous treatment (n=2), impaired hepatic or renal function (n=2), or other (n=4). One patient refused treatment after randomization and is lost to follow up since. One patient aged 58 years was accidentally randomized, but this was considered a minor protocol violation and he has been included in the analysis. Of 419 remaining patients, 211 were randomized to arm A (control arm) and 208 were randomized to arm B, induction therapy with PSC-833. Median age was 67 years (range, 58-85). Patient baseline characteristics were comparable between the two arms ( Table 1) .
Cytogenetics
Successful cytogenetic data were available for 293 (70%) of the patients ( 
Response to chemotherapy
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Of 419 patients, 285 patients (68%) received induction cycles only and 128 patients (31%) received induction and consolidation treatment. 6/419 patients (1%) did not receive any protocol treatment (Figure 1 ).
Three of them received alternative induction therapy, resulting in a CR in 2 patients: one patient withdrew consent before cycle 1 and was treated with 6-mercaptopurine instead, and one patient with an adverse event before start treatment, who was then treated with idarubicin instead of daunorubicin. Both patients were considered as CR patients according to the intention to treat. The overall CR rate was 51%. CR was achieved in 101/211 patients (48%) in the control arm as compared with 112/208 patients (54%) in the PSC-833 arm (P = .22). 80 patients in arm A and 87 patients in arm B achieved a CR after the first induction cycle. Table 2 shows the CR rates by stratification factor. Induction failures were classified as refractory disease or as induction death in 79 (37%) respectively 31 (15%) patients in arm A, versus 63 (30%) respectively 33 (16%) patients in arm B. Early death rates were similar in both arms, 4 (2%) and 5 (2%) patients, respectively.
Event-free survival, disease-free survival and overall survival
The survival endpoints are based on follow up data available as of June 2004. The median follow up of 56 patients still alive is 56 months; 35 of these patients were still in continuous first CR at last contact, 19 in the control arm and 16 in the PSC-833 arm. Long-term EFS, DFS and OS were similar for both treatment groups (Table 3; Figure 2 ). 5-year EFS was 7% (95% CI 4-11) for the PSC-833 group as compared to 8% (5-13) for the control group (P = .53). The vast majority of patients who reached a CR, relapsed afterwards.
10 versus 14 patients died in CR, resulting in 5-year DFS of 17% (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) in the PSC-833 arm and 13% (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) in the control arm, P = .06. The 5-year OS was 10% (6-15) in both treatment arms, P = .52.
P-gp assessment
Viable BM samples to assess P-gp status at diagnosis were available in 309/419 patients (74%). The vast majority of samples were transported at 4°C. Only samples from the USA, Canada and Australia were cryopreserved before transportation. Ultimately, we had P-gp data of 35 patients with cryopreserved samples, which is 11% of all patients with P-gp data available. P-gp functional data were available in 282, and P-gp expression data were available in 293 patients. These data were highly correlated. Spearman's rank correlation coefficient between efflux ratio and MRK 16 expression ratio was 0.64 (P < .00001), while between MRK 16 and UIC2 expression ratio it was 0.81 (P < .00001). Of the 265 patients with both P-gp functional and expression data available, 11 patients had positive function and negative expression, while in 30 function was negative and expression positive. The 309 patients were classified as IPS negative (27%), low-positive (29%), intermediate-positive (28%) or high-positive (17%), with no difference between the two treatment arms (P = .91, Table 1 ). An increased IPS was associated with a lower CR rate; the CR rate decreased from 61% (95% CI 50-72) and 54% (95% CI 44-65) in the IPS negative respectively low-positive For personal use only. on July 15, 2017. by guest www.bloodjournal.org From patients to 49% (95% CI 38-60) and 40% (95% CI 27-55) in the IPS positive respectively high-positive patients (P = .02, test for trend). A higher IPS was also associated with significantly worse EFS and OS (Figure 3) , and a trend for decreased DFS was observed.
We also evaluated the mutual effect of PSC-833 and IPS on CR rate and survival. A multivariate logistic regression analysis of CR rate was performed with treatment arm, IPS and a treatment arm by IPS interaction term as covariates. EFS, DFS and OS were also evaluated, using multivariate Cox regression analyses. Similar results as in the univariate analyses were obtained. No benefit of PSC-833 was seen, while a higher IPS suggested a lower CR rate (OR = 0.75, 95% CI 0.54-1.03, P = .07), a significantly lower EFS (HR = 1.19, 95% CI 1.01-1.40, P = .04) and a trend for worse DFS (HR = 1.22, 95% CI 0.95-1.57, P = .12) and OS (HR = 1.12, 95% CI 0.95-1.32, P = .17). Detailed results for CR rate, EFS and OS are shown in Table 4 . However, none of the 4 analyses suggested an interaction between IPS and treatment arm.
Especially no greater benefit of PSC-833 was apparent with increasing IPS. This was illustrated by a subgroup analysis of the 227 patients with low-, intermediate-or high-positive IPS, who were expected to benefit most from PSC-833. Although CR rate was somewhat higher in the PSC-833 arm (55% vs. 44%, P = .07), survival was not better. Hazard ratios for PSC-833 were 1.02 (95% CI 0.78-1.33, P = .91) for EFS, 1.34 (95% CI 0.90-2.01, P = .15) for DFS and 1.03 (95% CI 0.78-1.35, P = .84) for OS, respectively.
Adverse events
Adverse events (AEs) affecting the central and peripheral nervous system and liver and biliary disorders were more frequently reported in the patients treated with PSC-833 + DNR than in those receiving DNR alone. More AEs related to the nervous system were reported in patients treated with PSC-833 + DNR, like paresthesia 16.3 vs. 1.9%, ataxia 13.9 vs. 1.4% or dizziness 26.2 vs. 11.3%, whereas excess liver AEs among the PSC-833 treatment group reflected more frequent reports of bilirubinemia 18.8 vs. 7.1%. The patterns of other reported AEs were similar for the 2 treatment arms (Table 5 ).
Premature discontinuation of chemotherapy due to non-fatal AEs were more frequent in the group treated with PSC-833 + DNR than in the group treated with DNR alone, 15.4% versus 9.5%. In both groups the most frequently reported reasons for premature discontinuation were infections, while discontinuations due to ataxia, cerebellar toxicity or peripheral neuropathy were only reported in patients treated with PSC-833 + DNR.
Deaths resulted from common complications of chemotherapy or from progression of AML. PSC-833, which is known to increase exposure to DNR by decreasing the clearance of the drug, did not lead to increased incidence or severity of chemotherapy-related AEs.
Discussion
Expression of the MDR1 gene has been associated with lower CR rates and worse OS and DFS in AML.
For personal use only. on July 15, 2017. by guest www.bloodjournal.org From This randomized phase 3 study of the P-gp inhibitor PSC-833 aimed at overcoming classical multidrug resistance in patients with AML of 60 years and older. It was designed to investigate whether the response of AML would improve by adding PSC-833 to standard induction treatment. This large study shows that PSC-833 does not improve response rate nor survival in patients with AML over 60 years. The overall CR rate was 51% and 5-year survival was 10% in both treatment arms, which is comparable with other published trials in this age group [1] [2] [3] [4] [5] . In order to establish the independent prognostic value of P-gp, an integrated P-gp status (IPS) of AML blasts was prospectively determined at diagnosis. In this laboratory analysis 73% of evaluable patients were classified as P-gp positive based on demonstrated P-gp reversal in vitro, which is in accordance with previously published data in this patient group 6 . We confirmed that IPS is an independent adverse prognostic factor in older patients with AML, as CR rate and EFS, DFS and OS decreased with increasing IPS. There was however no significant interaction between IPS and PSC-833 with regard to CR rate and survival endpoints.
Therapeutic P-gp reversal has been examined in several randomized phase 2 and phase 3 trials using firstgeneration P-gp modulators such as quinine and CsA.
Quinine did not show an improvement in CR rate and OS in two consecutive trials by the French GOELAM in mainly AML patients aged 15-65 years 22, 44 , while toxicity was significantly increased 22 . In the subgroup of patients who were tested for P-gp, a higher CR rate was observed in the 29 P-gp-positive patients in the quinine arm (83% versus 48%, P = .01) 44 .
The effect of CsA has been assessed in several trials in refractory and relapsed AML. In the UK MRC AML-R trial, OS and DFS did not differ between the CsA and the standard arm, while a lower CR rate due to increased induction deaths and resistant disease, and worse OS was observed in the subgroup of patients 
org From
trial was discontinued early due to lack of superiority in achieving CR in patients treated with PSC-833. In these trials there was no apparent difference in OS and DFS between the two arms, but the power to detect moderate differences was low due to the small patient numbers. The CALGB 19808 trial in AML patients < 60 years was halted in August 2003 because PSC-833 was no longer available 56 , and results are awaited.
Our study in significantly greater numbers of patients, with long follow up and with elaborate P-gp analysis failed to reveal a benefit for the use of PSC-833, while the independent prognostic value of P-gp at diagnosis was established. .
The study presented here shows that addition of the P-gp inhibition agent PSC-833 to standard induction chemotherapy does not improve CR rate, EFS, DFS and OS in patients aged 60 years and older. In addition, MDR1 status at diagnosis remains an independent adverse prognostic factor, indicating the need for other strategies to overcome MDR1 mediated resistance. 
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